Hala H Zreikat1, Spencer E Harpe1, Patricia W Slattum1, D'arcy P Mays2, Paulina A Essah3, Kai I Cheang4. 1. Department of Pharmacotherapy & Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA. 2. Department of Statistical Sciences and Operations Research, Virginia Commonwealth University, Richmond, VA, USA. 3. Department of Medicine, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA. 4. Department of Pharmacotherapy & Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA. Electronic address: kicheang@vcu.edu.
Abstract
OBJECTIVE: Metabolic syndrome (MetS) is associated with cardiovascular disease (CVD). Insulin resistance has been hypothesized as the underlying feature of MetS. Angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are widely used antihypertensives that may improve insulin sensitivity. The aim of the study is to evaluate the effect of ACEI/ARB on incident CVD events in older hypertensive patients with MetS. MATERIALS/ METHODS: We used the Cardiovascular Health Study, a prospective cohort study of individuals>65years of age to evaluate ACEI/ARB use and time to CVD events (including coronary and cerebrovascular events). The study included 777 subjects who had hypertension and ATP III-defined MetS, but free of CVD and diabetes at baseline. Cox regression models were used to evaluate the effect of ACEI/ARB as compared to other antihypertensives on the time to the first CVD events. RESULTS: ACEI/ARB use was associated with a decreased risk of CVD events (adjusted HR=0.658, 95 % C.I. [0.436-0.993]) compared to other antihypertensives. When CVD endpoints were evaluated separately, use of ACEI/ARB was associated with lower rates of angioplasty and coronary events (HR of 0.129 and 0.530 respectively, with 95 % CI [0.017-0.952] and [0.321-0.875]). CONCLUSIONS: ACEI/ARB use was associated with a lower risk of CVD events in older hypertensive patients with MetS, primarily due to a reduction in coronary events. The potential protective effect of ACEI/ARB on CVD events in older individuals with MetS will need further confirmation from prospective studies.
OBJECTIVE:Metabolic syndrome (MetS) is associated with cardiovascular disease (CVD). Insulin resistance has been hypothesized as the underlying feature of MetS. Angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are widely used antihypertensives that may improve insulin sensitivity. The aim of the study is to evaluate the effect of ACEI/ARB on incident CVD events in older hypertensivepatients with MetS. MATERIALS/ METHODS: We used the Cardiovascular Health Study, a prospective cohort study of individuals>65years of age to evaluate ACEI/ARB use and time to CVD events (including coronary and cerebrovascular events). The study included 777 subjects who had hypertension and ATP III-defined MetS, but free of CVD and diabetes at baseline. Cox regression models were used to evaluate the effect of ACEI/ARB as compared to other antihypertensives on the time to the first CVD events. RESULTS: ACEI/ARB use was associated with a decreased risk of CVD events (adjusted HR=0.658, 95 % C.I. [0.436-0.993]) compared to other antihypertensives. When CVD endpoints were evaluated separately, use of ACEI/ARB was associated with lower rates of angioplasty and coronary events (HR of 0.129 and 0.530 respectively, with 95 % CI [0.017-0.952] and [0.321-0.875]). CONCLUSIONS: ACEI/ARB use was associated with a lower risk of CVD events in older hypertensivepatients with MetS, primarily due to a reduction in coronary events. The potential protective effect of ACEI/ARB on CVD events in older individuals with MetS will need further confirmation from prospective studies.
Authors: Hanna-Maaria Lakka; David E Laaksonen; Timo A Lakka; Leo K Niskanen; Esko Kumpusalo; Jaakko Tuomilehto; Jukka T Salonen Journal: JAMA Date: 2002-12-04 Impact factor: 56.272
Authors: Enzo Bonora; Stefan Kiechl; Johann Willeit; Friedrich Oberhollenzer; Georg Egger; Riccardo C Bonadonna; Michele Muggeo Journal: Diabetes Care Date: 2003-04 Impact factor: 19.112
Authors: Yong-Woo Park; Shankuan Zhu; Latha Palaniappan; Stanley Heshka; Mercedes R Carnethon; Steven B Heymsfield Journal: Arch Intern Med Date: 2003-02-24
Authors: Bobby V Khan; Srikanth Sola; Wright B Lauten; Rama Natarajan; W Craig Hooper; Rekha G Menon; Stamatios Lerakis; Tarek Helmy Journal: Diabetes Care Date: 2004-07 Impact factor: 19.112
Authors: Michael W Manning; Mary Cooter; Joseph Mathew; John Alexander; Eric Peterson; T Bruce Ferguson; Renato Lopes; Mihai Podgoreanu Journal: Ann Thorac Surg Date: 2017-01-25 Impact factor: 4.330
Authors: Šefket Šabanović; Majnarić Trtica Ljiljana; František Babič; Michal Vadovský; Ján Paralič; Aleksandar Včev; Andreas Holzinger Journal: BMC Med Inform Decis Mak Date: 2018-04-02 Impact factor: 2.796